Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Amortizatization of Intangibles (2020 - 2025)

Historic Amortizatization of Intangibles for Eton Pharmaceuticals (ETON) over the last 6 years, with Q3 2025 value amounting to $189000.0.

  • Eton Pharmaceuticals' Amortizatization of Intangibles rose 55172.41% to $189000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 140961.54%. This contributed to the annual value of $70000.0 for FY2024, which is 4017.09% down from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Amortizatization of Intangibles stood at $189000.0, which was up 55172.41% from $48000.0 recorded in Q2 2025.
  • Eton Pharmaceuticals' Amortizatization of Intangibles' 5-year high stood at $1.0 million during Q4 2024, with a 5-year trough of $23000.0 in Q2 2024.
  • For the 5-year period, Eton Pharmaceuticals' Amortizatization of Intangibles averaged around $110473.7, with its median value being $36000.0 (2021).
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first plummeted by 6777.78% in 2023, then surged by 374814.81% in 2024.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Amortizatization of Intangibles stood at $38000.0 in 2021, then decreased by 18.42% to $31000.0 in 2022, then dropped by 12.9% to $27000.0 in 2023, then skyrocketed by 3748.15% to $1.0 million in 2024, then crashed by 81.81% to $189000.0 in 2025.
  • Its Amortizatization of Intangibles was $189000.0 in Q3 2025, compared to $48000.0 in Q2 2025 and $294000.0 in Q1 2025.